Mineralys Therapeutics Inc (NASDAQ:MLYS) price on Thursday, July 03, rose 1.68% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $14.54.
A look at the stock’s price movement, the close in the last trading session was $14.3, moving within a range at $14.2 and $14.63. The beta value (5-Year monthly) was -0.18. Turning to its 52-week performance, $18.38 and $8.24 were the 52-week high and 52-week low respectively. Overall, MLYS moved -10.14% over the past month.
Mineralys Therapeutics Inc’s market cap currently stands at around $947.65 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-12.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MLYS is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend MLYS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MLYS’s current price about 0.58% and -2.27% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.79, while 7-day volatility ratio is 4.51% and 5.25% in the 30-day chart. Further, Mineralys Therapeutics Inc (MLYS) has a beta value of -0.32. Analysts have given the company’s stock an average 52-week price target of $45, forecast between a low of $42 and high of $48. Looking at the price targets, the low is -188.86% off current price level while to achieve the yearly target high, price needs to move -230.12%. Nonetheless, investors will most likely welcome a -209.49% jump to $45 which is the analysts’ median price.
If we refocus on Mineralys Therapeutics Inc (NASDAQ:MLYS), historical trading data shows that trading volumes averaged 1.06 over the past 10 days and 875.05K over the past 3 months. The company’s latest data on shares outstanding shows there are 64.88 million shares.
The 37.70% of Mineralys Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 65.84% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.17 million on 2025-06-13, giving us a short ratio of 8.16. The data shows that as of 2025-06-13 short interest in Mineralys Therapeutics Inc (MLYS) stood at 1250.9999999999998 of shares outstanding, with shares short falling to 7.21 million registered in 2025-05-15. Current price change has pushed the stock 19.47% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MLYS stock continues to rise going into the next quarter.
